Triple
T19772733
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Array BioPharma |
E474928
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object | binimetinib |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: binimetinib | Statement: [Array BioPharma, developed, binimetinib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: binimetinib Context triple: [Array BioPharma, developed, binimetinib]
-
A.
binimetinib
chosen
Binimetinib is an oral MEK inhibitor used as a targeted cancer therapy, particularly in certain types of melanoma and other solid tumors.
-
B.
MEK inhibitor binimetinib
MEK inhibitor binimetinib is a targeted cancer therapy drug that blocks MEK enzymes in the MAPK signaling pathway to inhibit tumor cell growth and proliferation.
-
C.
encorafenib
Encorafenib is a small-molecule BRAF inhibitor used in targeted cancer therapy, particularly for tumors harboring BRAF V600 mutations.
-
D.
BRAF inhibitor encorafenib
BRAF inhibitor encorafenib is a targeted cancer therapy used primarily to treat tumors harboring specific BRAF mutations, such as certain forms of melanoma and colorectal cancer.
-
E.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e51a43a08190956bc6df13c91a77 |
completed | April 10, 2026, 11:55 a.m. |
| NER | Named-entity recognition | batch_69e6535ce4d08190a1dfca2df95a8631 |
completed | April 20, 2026, 4:25 p.m. |
Created at: April 10, 2026, 1:48 p.m.